EWCZ vs REGN

For growth investors, Regeneron Pharmaceuticals, Inc.

(REGN) is the stronger pick with 1. 0% revenue growth year-over-year, versus -1. 9% for European Wax Center, Inc. (EWCZ). Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 17. 4x trailing P/E (15. 3x forward), making it the more compelling value choice. Analysts rate Regeneron Pharmaceuticals, Inc. (REGN) a "Buy" — based on 48 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Regeneron Pharmaceuticals, Inc.

(REGN) is the cheapest at 17. 4x versus European Wax Center, Inc. at 26. 4x. On forward P/E, European Wax Center, Inc. is actually cheaper at 8. 5x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Regeneron Pharmaceuticals, Inc.

(REGN) delivered a total return of +45. 4%, compared to -57. 5% for European Wax Center, Inc. (EWCZ). Over 10 years, the gap is even starker: REGN returned +90. 0% versus EWCZ's -57. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Regeneron Pharmaceuticals, Inc.

(REGN) is the lower-risk stock at 0. 81β versus European Wax Center, Inc. 's 1. 46β — meaning EWCZ is approximately 81% more volatile than REGN relative to the S&P 500. On balance sheet safety, Regeneron Pharmaceuticals, Inc. (REGN) carries a lower debt/equity ratio of 9% versus 4% for European Wax Center, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Regeneron Pharmaceuticals, Inc.

(REGN) is pulling ahead at 1. 0% versus -1. 9% for European Wax Center, Inc. (EWCZ). On earnings-per-share growth, the picture is similar: European Wax Center, Inc. grew EPS 29. 4% year-over-year, compared to 8. 2% for Regeneron Pharmaceuticals, Inc.. Over a 3-year CAGR, EWCZ leads at 6. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Regeneron Pharmaceuticals, Inc.

(REGN) is the more profitable company, earning 31. 4% net margin versus 4. 8% for European Wax Center, Inc. — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: REGN leads at 24. 9% versus 22. 0% for EWCZ. At the gross margin level — before operating expenses — REGN leads at 85. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, European Wax Center, Inc.

(EWCZ) trades at 8. 5x forward P/E versus 15. 3x for Regeneron Pharmaceuticals, Inc. — 6. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for REGN: 20. 1% to $865. 68.

All stocks in this comparison pay dividends.

Regeneron Pharmaceuticals, Inc. (REGN) offers the highest yield at 0. 5%, versus 0. 3% for European Wax Center, Inc. (EWCZ).

For long-horizon retirement investors, Regeneron Pharmaceuticals, Inc.

(REGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 81)). Both have compounded well over 10 years (REGN: +90. 0%, EWCZ: -57. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (EWCZ (Consumer Defensive) and REGN (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: EWCZ is a small-cap quality compounder stock; REGN is a mid-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.